BCR and chronic myelogenous leukemia, BCR-ABL1 positive: For example, Shah and co-workers [38] demonstrate that the BCR-ABL inhibitor dasatinib, which has greater potency and a short half-life, can achieve deep clinical remission in CML patients by achieving transient potent BCR-ABL inhibition, while traditional approved tyrosine kinase inhibitors usually have prolonged half lives resulting in continuous target inhibition.